Zymergen Inc. Overview
Pro stress-test →Zymergen is a biotechnology company that specializes in designing and producing molecules, microbes, and materials for diverse end markets through the use of genomics and machine learning. The company has experienced significant challenges post-IPO and now trades as a public company with a market cap of approximately $254M.
Strategic Profile
Pro stress-test →Ginkgo Bioworks agreed to acquire Zymergen for $300 million in July 2022, though the company remains publicly traded. After going public in April 2021, the company faced manufacturing difficulties and revealed in August 2021 that its flagship Hyaline product was unsuccessful, causing stock prices to plunge. The company has restructured around three business pillars: Advanced Materials, Drug Discovery, and Automation.
Competitive Landscape
Pro stress-test →Zymergen's competitors include Standard BioTools, BioTork, Ingenza, Arzeda, and Twist Bioscience. The company operates in the synthetic biology and gene-edited materials space, competing with both established biotech firms and younger synthetic biology platforms.
Industry Context
Zymergen Inc. operates in Synthetic Biology / Biotechnology.
Key facts
Founded: 2013 · Headquarters: Emeryville, US · Employees: 49 · Market cap: $254M